With Australia's Cheaper Home Batteries Program offering a 30% subsidy on home energy storage, Swatten's latest Single-Phase Hybrid Inverter (8/10kW) and flagship All-in-One (5-20kW) System and ...

Shortly after paying $800 million to take full control of BNT327, the biotech began a phase 3 trial to test the bispecific ... 48 patients in the open-label, single-arm trial had completed at ...

A pen­ny stock biotech re­port­ed that its acute graft-ver­sus-host dis­ease drug failed a late-stage tri­al, but it still plans to seek ac­cel­er­at­ed ap­proval.

XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne- - Over 30 million acne patients seek ...

A phase 3 trial will evaluate IMNN-001, the first immunotherapy to show an overall survival benefit in ovarian cancer. The FDA-aligned with a protocol to evaluate IMNN-001 with neoadjuvant ...

GameSpot may get a commission from retail offers. The Nintendo Switch 2 is reportedly launching in June, with a three-phase plan for rolling out both first- and third-party games throughout the ...

Months after seeing one phase 3 trial fail, the biotech is planning ... before Cassava pulled the plug, ReFocus-ALZ still offered the biotech a final chance to show simufilam may be effective ...

Will Nintendo really follow suit with the Switch 2? Not only that, but Nintendo will supposedly implement a three-phase plan for its Switch 2 software, with first-party titles getting top priority ...

Nintendo has reportedly set a three-phase launch plan for its hotly anticipated gaming console, Switch 2. According to a report by Insider Gaming, the company is planning to launch its sequel ...

9 Nintendo Switch 2 Games It NEEDS to Have - Super Mario Odyssey 2 & More! Watch on YouTube The second phase of Nintendo's game launch plan is then reportedly set for around October-November ...

LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 ...